556 related articles for article (PubMed ID: 19144424)
1. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction.
Jeong YH; Kim WJ; Park DW; Choi BR; Lee SW; Kim YH; Lee CW; Hong MK; Kim JJ; Park SW; Park SJ
Int J Cardiol; 2010 May; 141(2):175-81. PubMed ID: 19144424
[TBL] [Abstract][Full Text] [Related]
2. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty.
Grabowski M; Filipiak KJ; Karpinski G; Wretowski D; Rdzanek A; Huczek Z; Horszczaruk GJ; Kochman J; Rudowski R; Opolski G
Am Heart J; 2004 Oct; 148(4):655-62. PubMed ID: 15459597
[TBL] [Abstract][Full Text] [Related]
3. Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Seo SM; Kim S; Chang K; Min J; Kim TH; Koh YS; Park HJ; Shin WS; Lee JM; Kim PJ; Chung WS; Seung KB
Coron Artery Dis; 2011; 22(6):405-10. PubMed ID: 21701385
[TBL] [Abstract][Full Text] [Related]
4. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation.
Zhang Q; Zhang RY; Shen J; Zhang JS; Hu J; Yang ZK; Zhang X; Zheng AF; Shen WF
Chin Med J (Engl); 2008 Dec; 121(23):2379-83. PubMed ID: 19102952
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score.
Kuklinska AM; Sobkowicz B; Mroczko B; Sawicki R; Musial WJ; Knapp M; Dobrzycki S; Szmitkowski M
Clin Chim Acta; 2007 Jul; 382(1-2):106-11. PubMed ID: 17482153
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
Mega JL; Morrow DA; De Lemos JA; Sabatine MS; Murphy SA; Rifai N; Gibson CM; Antman EM; Braunwald E
J Am Coll Cardiol; 2004 Jul; 44(2):335-9. PubMed ID: 15261928
[TBL] [Abstract][Full Text] [Related]
8. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
[TBL] [Abstract][Full Text] [Related]
9. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
[TBL] [Abstract][Full Text] [Related]
10. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty.
Grabowski M; Filipiak KJ; Malek LA; Karpinski G; Huczek Z; Stolarz P; Spiewak M; Kochman J; Rudowski R; Opolski G
Int J Cardiol; 2007 Feb; 115(3):386-90. PubMed ID: 16860415
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention.
Niccoli G; Giubilato S; Russo E; Spaziani C; Leo A; Porto I; Leone AM; Burzotta F; Riondino S; Pulcinelli F; Biasucci LM; Crea F
Eur Heart J; 2008 Aug; 29(15):1843-50. PubMed ID: 18617477
[TBL] [Abstract][Full Text] [Related]
12. Impact of admission glomerular filtration rate on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.
Celik T; Iyisoy A; Yuksel CU; Kilic S; Yilmaz MI; Akgul EO; Jata B; Isik E
Coron Artery Dis; 2008 Dec; 19(8):543-9. PubMed ID: 19005288
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction.
Hong SN; Ahn Y; Hwang SH; Yoon NS; Lee SR; Moon JY; Kim KH; Hong YJ; Park HW; Kim JH; Jeong MH; Cho JG; Park JC; Kang JC
Am J Cardiol; 2007 Aug; 100(4):631-4. PubMed ID: 17697819
[TBL] [Abstract][Full Text] [Related]
14. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
Akpek M; Kaya MG; Lam YY; Sahin O; Elcik D; Celik T; Ergin A; Gibson CM
Am J Cardiol; 2012 Sep; 110(5):621-7. PubMed ID: 22608360
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
[TBL] [Abstract][Full Text] [Related]
16. In-hospital prognostic value of admission plasma B-type natriuretic peptide levels in patients undergoing primary angioplasty for acute ST-elevation myocardial infarction.
Oduncu V; Erkol A; Tanalp AC; Dündar C; Tanboğa IH; Sırma D; Karagöz A; Karabay CY; Izgi A; Pala S; Tigen K; Kırma C
Turk Kardiyol Dern Ars; 2011 Oct; 39(7):540-8. PubMed ID: 21983763
[TBL] [Abstract][Full Text] [Related]
17. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Zhao L; Wang L; Zhang Y
J Invasive Cardiol; 2009 Oct; 21(10):493-8. PubMed ID: 19805833
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the usefulness of N-terminal pro-brain natriuretic peptide to other serum biomarkers as an early predictor of ST-segment recovery after primary percutaneous coronary intervention.
Verouden NJ; Haeck JD; Kuijt WJ; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; van Straalen JP; Fischer J; Piek JJ; Tijssen JG; de Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1047-52. PubMed ID: 20381651
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Wang JW; Chen YD; Wang CH; Yang XC; Zhu XL; Zhou ZQ
Cardiology; 2013; 124(3):153-60. PubMed ID: 23485798
[TBL] [Abstract][Full Text] [Related]
20. B-type natriuretic peptide predicts new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Asanin M; Stankovic S; Mrdovic I; Matic D; Savic L; Majkic-Singh N; Ostojic M; Vasiljevic Z
Peptides; 2012 May; 35(1):74-7. PubMed ID: 22421508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
